PLEASE TELL US A LITTLE ABOUT YOURSELF SO THAT WE CAN DISPLAY THE MOST
APPROPRIATE CONTENT TO YOU:

This site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about cookies used on Trustnet and how you can manage them, see our Privacy and Cookie Policy.

By clicking "I Agree" below, you acknowledge that you accept our Privacy Policy and Terms of Use.

For more information Click here

Login

Register

It's look like you're leaving us

What would you like us to do with the funds you've selected

Show me all my options Forget them Save them
Customise this table
Share   Print      RSS

Advanced Oncotherapy (AVO)

Advanced Oncotherapy

Result of AGM
RNS Number : 7804G
Advanced Oncotherapy PLC
25 July 2019
 

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

 

Result of AGM

 

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that at the Annual General Meeting held earlier today, all resolutions were passed on a show of hands. The results of the proxy voting for the AGM is set out below:

 

Resolution

Total votes For1

% of votes cast2

Total Votes Against

% of votes cast2

Votes Withheld3

1.     To receive the audited financial statements and the Auditor's and Directors' reports for the year ended 31 December 2018.

84,274,491

99.99

7,976

0.01

1,130

2.     To re-appoint Michael Bradfield as a Director of the Company.

84,273,267

99.99

10,330

0.01

0

3.     To appoint Chunlin Han as a Director of the Company.

84,272,751

99.99

10,846

0.01

0

4.     To re-appoint Hans von Celsing as a Director of the Company.

84,273,267

99.99

10,330

0.01

0

5.     To appoint Dr. Yuelong Huang as a Director of the Company.

84,272,751

99.99

10,846

0.01

0

6.     To re-appoint Prof Steve Myers as a Director of the Company.

84,273,010

99.99

10,330

0.01

257

7.     To re-appoint Dr Nick Plowman as a Director of the Company.

84,273,010

99.99

10,330

0.01

257

8.     To re-appoint Nicolas Serandour as a Director of the Company.

84,273,010

99.99

10,330

0.01

257

9.     To re-appoint Dr Michael Sinclair as a Director of the Company.

84,272,844

99.99

10,496

0.01

257

10.  To appoint Peter Sjöstrand as a Director of the Company.

84,273,010

99.99

10,330

0.01

257

11.  To appoint Prof. Gabriel Urwitz as a Director of the Company.

84,273,010

99.99

10,330

0.01

257

12.  To re-appoint Dr Enrico Vanni as a Director of the Company.

84,273,010

99.99

10,330

0.01

257

13.  To appoint Renhua Zhang as a Director of the Company.

84,272,751

99.99

10,846

0.01

0

14.  To re-appoint RPG Crouch Chapman LLP as Auditors

84,274,104

99.99

7,976

0.01

1,517

15.  To authorise the Directors to determine the remuneration of the Auditors.

84,272,837

99.99

9,930

0.01

830

16.  Authority to allot shares

 

84,267,634

99.98

15,797

0.02

166

17.  Authority to disapply pre-emption rights

 

84,212,134

99.92

71,297

0.08

166

 

At the AGM the Company gave a presentation to shareholders. This will shortly be available on the website:

https://www.avoplc.com/Investor-Relations/Company-Documents

 

Notes:

 

1.     Any proxy votes that were at the discretion of the Chairman are included in the "Total Votes For" each resolution

2.     Percentage of votes cast excludes Votes Withheld

3.     Votes Withheld are not votes in law and do not count in the number of votes counted for or against a resolution

 

 

Advanced Oncotherapy Plc

www.avoplc.com

Dr. Michael Sinclair, Executive Chairman

Tel: +44 (0)20 3617 8728

Nicolas Serandour, CEO




Allenby Capital Limited (Nominated Adviser & Joint Broker)


Nick Athanas / Liz Kirchner / Nicholas Chambers

Tel: +44 (0)20 3328 5656



Stifel Nicolaus Europe (Joint Broker)


Jonathan Senior

Tel: +44 20 7710 7600



Walbrook PR (Financial PR & IR)

Tel: +44 (0)20 7933 8780 or avo@walbrookpr.com

Paul McManus / Anna Dunphy

Mob: +44 (0)7980 541 893 / Mob: +44 (0)7876 741 001

 

 

About Advanced Oncotherapy Plc www.avoplc.com

 

Advanced Oncotherapy is a provider of particle therapy in the treatment of cancer, which harnesses the very best in modern technology. Advanced Oncotherapy's R&D team, ADAM, in Geneva, focuses on the development of a proprietary proton accelerator - LIGHT (Linac Image Guided Hadron Technology). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a compact and truly modular unit, offering significant cost advantages. LIGHT also delivers proton beams in a way that facilitates greater precision and electronic control, which are not achievable with currently available alternative technologies.

 

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology, offering better health outcomes and lower treatment related side effects.

 

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton or particle therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of cutting edge, cost-effective systems for particle therapy. 

 

Due to the high cost of building and operating traditional proton therapy technologies has meant that the global capacity to treat cancer patients in this way has been extremely low. Only 1% of patients eligible for radiotherapy are being treated with proton therapy currently, with a capacity for as little as 60,000 patients to be treated annually across the globe. Considering the UK alone, where roughly 360,000 patients are diagnosed with cancer each year, it is clear that there is a desperate clinical need for the roll-out of a technology that can bring the benefits of proton beam therapy to millions of patients worldwide.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RAGSEFFMIFUSEFW
Data provided by FE fundinfo. Care has been taken to ensure that the information is correct, but FE fundinfo neither warrants, represents nor guarantees the contents of information, nor does it accept any responsibility for errors, inaccuracies, omissions or any inconsistencies herein. Past performance does not predict future performance, it should not be the main or sole reason for making an investment decision. The value of investments and any income from them can fall as well as rise.

You are currently using an old browser which will not be supported by Trustnet after 31/07/2016. To ensure you benefit from all features on the site, please update your browser.   Close